Journal Home
Search for

Volume 36, Issue 6, Pages 688-694 (December 2009)


View previous. 13 of 26 View next.

Concurrent chemoradiotherapy with adjuvant chemotherapy for high-risk nasopharyngeal carcinoma

Ching-Chih Leeabd, Sau-Tung ChucCorresponding Author Informationemail address, Pesus Choua

Received 4 January 2009; accepted 21 March 2009.

Abstract 

Objectives

To evaluate the impact of invasion of the prevertebral or parapharyngeal spaces and large tumor volume on treatment outcomes in patients with nasopharyngeal carcinoma (NPC).

Methods

A total of 105 patients with newly diagnosed NPC were enrolled in this study. TNM stage and presence of invasion of the prevertebral or parapharyngeal spaces were recorded. All patients received a total dose of 70–75Gy.

Results

After controlling for age, sex, and chemotherapy status, invasion of the prevertebral or parapharyngeal spaces and large primary tumor volume produced a significantly increased hazard ratio for distant metastasis and recurrence. We defined patients with two or more such prognostic factors as high-risk patients, in whom the 3-year metastasis-free survival rate, with and without adjuvant chemotherapy, was 100% and 69.6%, respectively (P=0.02). Their 3-year recurrence-free survival rate, with and without adjuvant chemotherapy, was 93.3% and 70.2% (P=0.09). This benefit was not observed in low-risk NPC patients.

Conclusion

NPC patients with any two or more of the factors, involvement of the prevertebral space, large primary tumor volume, or advanced parapharyngeal space invasion, had more recurrence and poor survival rates and benefited from concurrent chemoradiotherapy followed by adjuvant chemotherapy.

a Community Medicine Research Center and Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, ROC

b Department of Otolaryngology, Buddhist Tzu Chi Dalin General Hospital, Chiayi, Taiwan

c Department of Otolaryngology, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung 1st Road, Kaohsiung 81436, Taiwan, ROC

d School of Medicine, Tzu Chi University, Hualian, Taiwan, ROC

Corresponding Author InformationCorresponding author. Tel.: +886 5 2648000x5231; fax: +886 5 2648006.

PII: S0385-8146(09)00097-2

doi:10.1016/j.anl.2009.03.009


View previous. 13 of 26 View next.